Shrinking lung tumors before surgery: targeted drugs show promise for rare cancer type
NCT ID NCT07700836
First seen Jul 14, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study looks at whether giving targeted drugs called ROS1 inhibitors before surgery can help people with a rare form of lung cancer. The drugs, entrectinib or crizotinib, are designed to attack cancer cells with a specific genetic change. Researchers will check how much the tumor shrinks and how well surgery goes afterward.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ROS1 tyrosine kinase inhibitor drugs (entrectinib or crizotinib)
- What this could lead to
- If successful, this approach could make surgery more effective for people with this rare lung cancer, potentially improving long-term outcomes.
- What could go wrong
- This is a small, retrospective study with only 12 participants, so results may not apply to everyone. The drugs can cause side effects, and not all tumors may respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ROS1 FUSION-POSITIVE LUNG ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital & Institute, Beijing, Beijing 100142
Beijing, Beijing Municipality, 100142, China